Table 2.
The baseline characteristics for treatment group (RC) and placebo.
| RC (n = 29) | Placebo (n = 31) | p valuea | |
|---|---|---|---|
| Age, years | 52.65 (±0.85) | 52.28 (±0.42) | p > 0.05 |
| BMI | 26.01 (±0.97) | 25.45 (±0.60) | p > 0.05 |
| FSH, int.enh./L | 72.74 (±4.88) | 72.07 (±4.85) | p > 0.05 |
| Family history of osteoporosis (yes/no) | 6/29 | 5/26 | — |
| DXA | |||
| BMD lumbar spine, g/cm2 | 1.06 (±0.04) | 1.05 (±0.04) | p > 0.05 |
| BMD femoral neck, g/cm2 | 0.913 (±0.02) | 0.85 (±0.02) | p > 0.05 |
| BMC, lumbar spine, g | 50.49 (±2.16) | 48.34 (±1.57) | p > 0.05 |
| BMC, femoral neck, g | 4.31 (±0.13) | 4.09 (±0.09) | p > 0.05 |
| T-score, lumbar spine, SD | −0.23 (±0.39) | −0.36 (±0.23) | p > 0.05 |
| T-score, femoral neck, SD | −0.06 (±0.20) | −0.57 (±0.17) | p > 0.05 |
| Biochemical marker | |||
| Ctx ng/mL | 0.48 (±0.05) | 0.54 (±0.03) | p > 0.05 |
| 24-hour blood pressure | |||
| (i) Systolic mmHg | 125.0 (±1.89) | 124.5 (±2.21) | p > 0.05 |
| (ii) Diastolic mmHg | 78.9 (±1.36) | 78.2 (±1.26) | p > 0.05 |
aRepresenting p value between groups at baseline. Data are presented as mean (±SEM).